Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals Inc (BCRX) is a biotechnology leader developing innovative therapies for rare diseases and infectious conditions through targeted enzyme inhibition. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative reporting on BCRX's pipeline progress, including updates on hereditary angioedema treatments and antiviral therapies. Our curated collection features earnings announcements, research breakthroughs, and partnership disclosures – all essential for tracking this biopharma innovator.
Key updates include FDA decisions, clinical trial results, and scientific publications. Bookmark this page for streamlined access to verified BioCryst news, eliminating the need to monitor multiple sources. Check regularly for developments impacting the company's position in enzyme inhibitor therapeutics and rare disease treatment markets.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced it will release its first quarter 2025 financial results on Monday, May 5, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring management discussion of financial results and a corporate update.
Interested parties can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section at www.biocryst.com.
BioCryst Pharmaceuticals (BCRX) has granted restricted stock units (RSUs) to 10 newly-hired employees as employment inducements. The grants, approved by the compensation committee, cover a total of 65,500 shares of BioCryst common stock and were issued on April 1, 2025.
The RSUs are structured to vest in four equal annual installments, with the first vesting occurring on the one-year anniversary of the grant date. Vesting is contingent upon continued employment with BioCryst. These equity awards were granted under BioCryst's Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Wednesday, April 9, 2025, at 9:30 a.m. ET.
Investors and interested parties can access both the live audio webcast and a replay of the presentation through the Investors & Media section on BioCryst's official website at http://www.biocryst.com.
BioCryst Pharmaceuticals (BCRX) has announced the granting of restricted stock units (RSUs) to seven newly-hired employees. The compensation committee approved RSUs covering 65,900 shares of BioCryst common stock, granted on March 3, 2025. These inducement grants, issued under Nasdaq Listing Rule 5635(c)(4), will vest over four equal annual installments starting from the one-year anniversary of the grant date. The vesting is contingent upon continued employment with the company. The RSUs are governed by BioCryst's Inducement Equity Incentive Plan and respective RSU agreements.
BioCryst Pharmaceuticals (BCRX) reported strong Q4 and full year 2024 results, with ORLADEYO net revenue reaching $124.2M in Q4 (+36.6% y-o-y) and $437.7M for FY 2024 (+34.3% y-o-y). The company increased its FY 2025 ORLADEYO revenue guidance to $535-550M.
The company achieved a non-GAAP operating profit of $62.9M in 2024 (excluding stock-based compensation) and expects to approach positive EPS and cash flow in 2H 2025. GAAP operating loss for 2024 was $2.5M, with Q4 net loss at $26.8M ($0.13 per share).
Key pipeline developments include plans to expand ORLADEYO label to children aged 2-11, with NDA submission planned this year. Initial clinical data from BCX17725 for Netherton syndrome and avoralstat for diabetic macular edema are expected by year-end. Cash position stood at $342.8M as of December 31, 2024.
BioCryst Pharmaceuticals (BCRX) announced positive interim results from the APeX-P trial evaluating ORLADEYO® in pediatric HAE patients aged 2 to <12 years. The trial, the largest evaluating prophylactic HAE therapy in this age group, demonstrated that the oral granule formulation was safe and well-tolerated.
Key findings show that after one month of ORLADEYO treatment, median monthly attack rates dropped from 0.96 to 0, maintaining this level through month 12. The mean monthly attack rate decreased from 1.5 to 0.3 attacks at month 12.
Additional real-world evidence presented showed statistically significant HAE attack rate reductions in patients with C1-INH deficiency and normal C1-INH levels. Patients experiencing ≥5 baseline attacks/month showed the largest reductions, with 6.20 fewer attacks/month at 12 months. The company plans to submit a New Drug Application to the FDA this year.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced its participation in two major upcoming investor conferences in March 2025. The company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5 at 9:10 a.m. ET, and at the Barclays 27th Annual Global Healthcare Conference in Miami on March 11 at 10:00 a.m. ET.
Investors and interested parties can access live audio webcasts and replay recordings of both presentations through the Investors & Media section of BioCryst's website at biocryst.com.
BioCryst Pharmaceuticals (BCRX) has received a recommendation from Infarmed in Portugal for ORLADEYO® (berotralstat), marking its entry into the Portuguese market. The drug is approved for routine prevention of recurrent hereditary angioedema (HAE) attacks in patients aged 12 and older.
ORLADEYO is significant as the first oral, once-daily therapy for HAE attack reduction in Portugal. This follows the European Commission's marketing authorization granted in April 2021. The drug is now licensed in 44 countries globally, expanding BioCryst's international market presence.
BioCryst Pharmaceuticals (BCRX) has announced plans to present five abstracts featuring new clinical and real-world outcomes of ORLADEYO® (berotralstat) at the 2025 AAAAI/WAO joint congress in San Diego. The presentations will include a significant late-breaking abstract showcasing the first results from the APeX-P trial, which evaluates ORLADEYO in pediatric HAE patients aged 2 to <12 years.
The presentations, scheduled for March 2, 2025, will cover various aspects including: HAE attack rates in pediatric patients, real-world attack rates before and after berotralstat initiation in different patient groups, patient willingness to change long-term prophylaxis, and patient-reported impact of berotralstat as long-term prophylaxis. All abstracts are accessible through The Journal of Allergy and Clinical Immunology's online supplement.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced it will release its fourth quarter 2024 financial results on Monday, February 24, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day, where management will discuss financial results and provide a corporate update. Interested parties can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section of BioCryst's website.
